Skip to main content
    N

    Nautilus Biotechnology Inc (NAUT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.10
    -0.22 (-9.48%)

    Market Cap: $295.50M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nautilus Biotechnology Inc (NAUT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Nautilus Biotechnology (NAUT) to earn -$0.49 per share in the fiscal year ending Dec 31, 2026, on revenue of $668500. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.49.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy4100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus is unchanged and revenue estimates rise 763.1%.

    Fiscal year ending Dec 31, 2026
    -$0.49
    EPS consensus, revenue $668500
    Fiscal year ending Dec 31, 2027
    -$0.49
    EPS consensus, revenue $5.77M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.49-$0.50 to -$0.444$668500$600000 to $7000004
    Dec 31, 2027-$0.49-$0.55 to -$0.394$5.77M$4.80M to $8.10M4

    Quarterly Estimates

    The EPS consensus rises from -$0.14 for the quarter ending Dec 31, 2026 to -$0.12 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.14-$0.15 to -$0.116$267750$196000 to $3150006
    Mar 31, 2027-$0.12-$0.14 to -$0.093$387500$200000 to $5000004

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.51.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.49-$0.51-$0.51-$0.51-$0.51N/A
    Fiscal year ending Dec 31, 2027-$0.49-$0.52-$0.52-$0.52-$0.52N/A
    Quarter ending Mar 31, 2027-$0.12-$0.12-$0.12-$0.09-$0.09N/A

    Frequently Asked Questions About NAUT

    What is the NAUT stock forecast?

    Consensus analyst estimates put Nautilus Biotechnology's EPS at -$0.49 for the fiscal year ending Dec 31, 2026, on revenue of $668500. The consensus rating from 4 analysts is Buy.

    How do analysts rate NAUT stock?

    Of 4 analysts covering Nautilus Biotechnology, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from NAUT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.49, with estimates from -$0.50 to -$0.44 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.49, with estimates from -$0.55 to -$0.39 from 4 analysts.

    What revenue do analysts expect from Nautilus Biotechnology next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $668500, with estimates from $600000 to $700000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5.77M, with estimates from $4.80M to $8.10M.

    How many analysts cover NAUT?

    4 analysts rate Nautilus Biotechnology stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.